Medicines By Design

Learn More

Recent Press Releases

January 19, 2021: miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
December 17, 2020: miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
November 10, 2020: miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
October 28, 2020: miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
October 5, 2020: miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)